Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 20 versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 20 versus LEVORA 0 15 30 21.
AUROVELA 1/20 vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive